Author:
Jin Shengming,Wei Jiaming,Wang Junjie,Wang Beihe,Wu Junlong,Gan Hualei,Dai Bo,Qin Xiaojian,Lin Guowen,Wei Yu,Yang Chen,Shen Yijun,Zhu Yiping,Zhu Yao,Ye Dingwei
Abstract
PurposeOur study aims to examine the impact of definitive local therapy in prostate cancer patients with different metastatic sites.MethodsTotally, 5,849 patients diagnosed with metastatic prostate carcinoma from 2010 to 2014 were selected from Surveillance, Epidemiology, and End Results (SEER). Log-rank analyses, multivariable regression analysis, and Kaplan–Meier methods were used to assess prognostic impact of local treatment in patients with different metastatic sites. Survival curves and forest plots were also plotted to describe the prognostic value of definitive local therapy.ResultsIn our study, 159 patients received radical prostatectomy, and 62 received brachytherapy, while 5,628 did not receive local definitive local therapy. Survival analysis revealed that patients who received definitive local therapy had a better 5-year overall survival (OS) (P = 0.011) and cancer-specific survival (CSS) (P = 0.012). Multivariate regression analyses demonstrated that type of treatment was an independent prognostic indicator for OS (P = 0.011) and CSS (P = 0.012), along with age at diagnosis, chemotherapy, PSA level, and Gleason score. According to subgroup analysis, patients with bone metastasis or distant lymph node (LN) metastasis were significantly more likely to benefit from definitive local therapy. In addition, forest plots demonstrated that RP group had significant favorable OS and CSS in subgroups of younger age at diagnosis, T2–3 stage, N0–1 stage, Gleason score =7 or ≥8, bone metastasis, and distant LN metastasis.ConclusionsOur study suggested that local therapy improved survival in prostate cancer patients with bone or distant LN metastasis. Furthermore, patients who were at T2–3 stage or Gleason score ≥7 also significantly benefit from definitive local therapy.
Reference27 articles.
1. Cancer statistics, 2018;Siegel;CA: Cancer J Clin,2018
2. Cancer treatment and survivorship statistics, 2016;Miller;CA: Cancer J Clin,2016
3. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology;Mohler;J Natl Compr Canc Netw,2019
4. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis;Gandaglia;Prostate,2014
5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer;Cornford;Eur Urol,2017